Roivant Sciences (ROIV)

• Market cap: $15.2B
• 1 day: -0.9%
• 5 days: 4.83%
• 1 month: 6.52%
• 3 months: 56.99%
• 6 months: 97.65%
• Year to date: 81.29%
• 1 year: 80.99%
• 5 years: 134.22%
• 10 years: 134.22%
• Sector: Healthcare
• Industry: Biotechnology

About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Employees: 750